Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

Launching Excellence
in ADHD Patient
Group Awards 

Read how the 2014 Awards program has captured the interest of numerous organizations around the world.

Read more

Shire completes acquisition of Lumena

Lumena is an excellent strategic fit that will enhance Shire’s commitment to patients with life-altering conditions and the Company’s rare disease portfolio and GI business unit.

View the Press Release


Shire's Stance 

Shire opposes the misuse, abuse, and diversion of prescription ADHD medicines.

Read more here


Shire's Clinical Trials website serves as the source for Shire-sponsored clinical trials, as well as a resource for education and awareness about clinical research. It also provides increased transparency into Shire’s data sharing practices.


2013 Annual Report

We are focused on growing Shire by developing and marketing innovative specialty medicines that address significant unmet patient needs.

View our Annual Report

Download our Annual Report 2013 (PDF)

Share price

23 Oct 2014
At least 15 minutes delayed

Our products

Shire has a wide range of products on the market and will ensure that it can make more products available in the future.


Our responsibility

We're pleased to announce that we have again been recognized as a constituent of the FTSE4Good Index Series. Read more


What Responsibility Means

What Responsibility means to Shire. Read more here.

Our stance on ADHD

Shire Opposes Misuse, Abuse and
Diversion of Prescription ADHD
Medicines. Read more here.